Dr. Shilpa Devanagondi, MD

Dr. Devanagondi practices at Sharp Rees-Stealy Medical Group, Inc in San Diego, California.

Dr. Devanagondi's NPI, 1609497221, was assigned on May 5, 2020. Dr. Devanagondi holds California license A191017.

Dr. Devanagondi's primary practice is Sharp Rees-Stealy Medical Group, Inc, at 5651 Copley Dr, San Diego, CA 92111 in San Diego County. The practice phone is (858) 262-6666.

Dr. Devanagondi's primary practice is Sharp Rees-Stealy Medical Group, Inc in San Diego, California. The medical group on file is Sharp Rees-Stealy Medical Group. Dmand AI also links Dr. Devanagondi to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Devanagondi practices. Vendor and product names are available with a free account.

Family medicine is Dr. Devanagondi's primary specialty in the NPI Registry, under taxonomy code 207Q00000X. Dr. Devanagondi is licensed in California.

CMS data shows 138 Medicare services from Dr. Devanagondi across 1 procedure code in 2024, all of them office visits, for 158 Medicare patients. Medicare paid $8,798 for them. Every service was in an office.

CMS counts 158 Medicare patients who saw Dr. Devanagondi in 2024. The largest group is 65 to 74, with 81 patients. 61% of them have high blood pressure, and 59% have high cholesterol. 13% are also on Medicaid. Their average risk score is 0.80, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Devanagondi's median patient age at 52, with 75% women.

In 2024, Dr. Devanagondi wrote 795 Medicare Part D claims for 312 patients. 86% of them were for generic drugs. CMS names the drug for 332 of them, across 18 drugs with 11 or more claims each, at $40,538 in total drug cost. In 2022, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Devanagondi for performance year 2024, reported as part of a group. Dr. Devanagondi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Devanagondi as offering telehealth.

CMS Open Payments shows 1 general payment to Dr. Devanagondi from 1 drug or device company in 2023. Food and beverage make up the largest share, 100% of the total. Idorsia Pharmaceuticals US Inc paid the most, $23.